AGP Picks
View all

Health Times of Rhode Island: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Times of Rhode Island.

Press releases published on May 18, 2026

Novastra Therapeutics Appoints Chief Financial Officer as Company Advances Lead Candidate Toward Global Clinical Development
Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models
BrainsWay Announces Minority-Stake Investment in Hopemark Health
Zenflow Presents the BREEZE™ Pivotal Clinical Trial at the American Urological Association Annual Meeting
CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates
NYU Langone Issues $580,000 Purchase Order for Inspira's FDA-Cleared ART100 Following Multi-Patient Hospital Evaluation
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
Nature Human Behaviour study finds SilverCloud® by Amwell® reduced prevalence of mental disorders over two years at scale
Kraig Biocraft Laboratories Announces Breakthrough Creation of Immortalized Silkworm Silk Gland Cell Line with Broad Biotechnology Applications
Byondis Establishes Scientific Advisory Board of Recognized Leaders in Oncology Research and ADC Development
Juniper Biosciences Appoints Renowned Radiopharmaceutical Expert Jason S. Lewis, Ph.D. as Chair of Newly Formed Scientific Advisory Board
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
One Fire, Many Flames: The Immune Response Fueling Allergic and Inflammatory Diseases
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
SEED Therapeutics to Present Phase 1 Trial Design for ST-01156, a First-in-Human Oral RBM39 Molecular Glue Degrader, at 2026 ASCO Annual Meeting
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

Share this page:

Sign up for:

Health Times of Rhode Island

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.